SCHEMBL7057094

SCHEMBL7057094

CCOC(=O)C(=O)CCc1ccc(Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAAT3 P53816 4/20 0.58
PLAAT5 Q96KN8 4/20 0.58
PLAAT2 Q9NWW9 4/20 0.58
PLAAT4 Q9UL19 4/20 0.58
CYP4F2 P78329 1/20 0.50
CYP4A11 Q02928 1/20 0.50
ALDH1A1 P00352 4/20 0.49
GAA P10253 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
POLB P06746 2/20 0.44
KDM4E B2RXH2 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
MAPT P10636 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C19 P33261 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ABCB11 O95342 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11041861 0.90 PLAAT3 (0.48) PLAAT3PLAAT5PLAAT2PLAAT4CYP4F2
SCHEMBL1149507 0.88 PLAAT3 (0.52) PLAAT3PLAAT5PLAAT2PLAAT4CYP4F2
SCHEMBL10420239 0.88 HDAC3 (0.51) PLAAT3PLAAT5PLAAT2PLAAT4ALDH1A1
SCHEMBL9726057 0.86 CYP4F2 (0.53) PLAAT3PLAAT5PLAAT2PLAAT4CYP4F2
SCHEMBL16596058 0.85 SMN1; SMN2 (0.43) PLAAT3PLAAT5PLAAT2PLAAT4CYP4F2
SCHEMBL1375513 0.85 CYP4F2 (0.51) CYP4F2CYP4A11ALDH1A1GAATDP1
SCHEMBL7059125 0.83 MAPT (0.51) PLAAT3PLAAT5PLAAT2PLAAT4CYP4F2
SCHEMBL4873306 0.83 CYP4F2 (0.50) PLAAT3PLAAT5PLAAT2PLAAT4CYP4F2
SCHEMBL95661 0.83 CYP4F2 (0.72) PLAAT3PLAAT5PLAAT2PLAAT4CYP4F2
SCHEMBL7060526 0.83 PLAAT3 (0.61) PLAAT3PLAAT5PLAAT2PLAAT4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11439622-B2 Inhibitors of metallo-beta-lactamases OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2022-09-13 US disclosed
CN-108602795-B Inhibitors of metallo-beta-lactamases 牛津大学科技创新有限公司 2022-04-22 CN disclosed
US-20200375946-A1 INHIBITORS OF METALLO-BETA-LACTAMASES OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2020-12-03 US disclosed
EP-3383858-A1 INHIBITORS OF METALLO-BETA-LACTAMASES Oxford University Innovation Limited (GB) 2018-10-10 EP disclosed
WO-2017093727-A1 INHIBITORS OF METALLO-BETA-LACTAMASES OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2017-06-08 WO disclosed
EP-0937703-B1 METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2003-05-21 EP disclosed
US-6348617-B1 REACTING PYRUVIC ACID COMPOUND IN WATER WITH AMMONIUM OR ALKALI METAL BISULFITE TO GIVE AQUEOUS SOLUTION OF BISULFITE ADDUCT, ISOLATING BY PHASE SEPARATION, OPTIONALLY USING HYDROPHOBIC SOLVENT, CONTACTING WITH ACID TO DECOMPOSE ADDUCT SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-02-19 US disclosed
EP-0937703-A1 METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1999-08-25 EP disclosed
US-5348944-A Hypotensive agents SCHERING CORPORATION (US) 1994-09-20 US disclosed
US-5098892-A Angiotensin converting enzyme inhibitors as hypotensive agents TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1992-03-24 US disclosed
US-4474692-A L-Alanyl-N-(indan-2-yl)glycine, its esters and salts thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1984-10-02 US disclosed
EP-0068173-B1 PERHYDRO-1,4-THIAZEPIN-5-ONE AND PERHYDRO-1,4-THIAZOCIN-5-ONE DERIVATIVES, PROCESS FOR PREPARING AND PHARMCEUTICAL COMPOSITION CONTAINING THE SAME MERCK & CO. INC. (US) 1984-09-26 EP disclosed
US-4472380-A CARBOXYALKYL DIPEPTIDE DERIVATIVES MERCK & CO., INC. (US) 1984-09-18 US disclosed
EP-0051391-B1 BICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1984-09-05 EP disclosed
US-4374829-A Aminoacid derivatives as antihypertensives MERCK & CO., INC. (US) 1983-02-22 US disclosed
EP-0068173-A1 Perhydro-1,4-thiazepin-5-one and perhydro-1,4-thiazocin-5-one derivatives, process for preparing and pharmceutical composition containing the same MERCK & CO. INC. (US) 1983-01-05 EP disclosed
EP-0065301-A1 Isoquinoline carboxylic acid derivates, process for preparing and pharmaceutical composition containing the same MERCK & CO. INC. (US) 1982-11-24 EP disclosed
EP-0051391-A1 Bicyclic compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1982-05-12 EP disclosed
EP-0050800-A1 Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them SCHERING CORPORATION (US) 1982-05-05 EP disclosed
EP-0012401-A1 Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them MERCK & CO. INC. (US) 1980-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11439622-B2 Inhibitors of metallo-beta-lactamases IDO1, MGAM, LCT PLAAT3 1199/4885PLAAT5 608/4885PLAAT2 542/4885
US-20200375946-A1 INHIBITORS OF METALLO-BETA-LACTAMASES IDO1, MGAM, LCT PLAAT3 1199/4885PLAAT5 608/4885PLAAT2 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.